Variation in gout care in Aotearoa New Zealand: A national analysis of quality markers

New Zealand Medical Journal

Volumn 127, Issue 1404, 2014, Pages 37-47

  Jackson, Gary ^a   Dalbeth, Nicola ^b   Te Karu, Leanne ^c   Winnard, Doone ^d   Gerard, Catherine ^f   Minko, Nikolai ^f  

^a Health Partners Consulting Group   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Turangi M ori Pharmacists Association   (New Zealand)

^d Population Health   (New Zealand)

^e MIDDLEMORE HOSPITAL   (New Zealand)

^f Health Quality and Safety Commission   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT;

ADULT; AGED; ARTICLE; FEMALE; GOUT; HEALTH CARE QUALITY; HOSPITAL ADMISSION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEW ZEALAND; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; CLINICAL PRACTICE; EPIDEMIOLOGY; ETHNOLOGY; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ALLOPURINOL; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; QUALITY INDICATORS, HEALTH CARE;

EID: 84922008506     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Winnard D, Wright C, Taylor WJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford) 2012;51(5):901–9.
2. Jackson G, Wright C, Thornley S, et al. Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset. Rheumatology (Oxford) 2012;51(10):1820–4.
3. Sivera F, Andrés M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014;73:328–335.
4. Khanna D, Fitzgerald JD, Khanna PP, et al. American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431–46.
5. An update on the management of gout - BPJ Issue 51. Available at: http://www.bpac.org.nz/BPJ/2013/March/managing-gout.aspx Accessed 1 Apr 2014.
6. Auckland Regional Clinical Pathways for Gout Prevention. Available at: http://www.healthpointpathways.co.nz/gout-prevention/ Accessed 1 Apr 2014.
7. Dalbeth N. Management of gout in primary care: challenges and potential solutions. Rheumatology (Oxford) 2013;52:1549-50.
8. Harrold LR, Mazor KM, Negron A, et al. Primary care providers’ knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. Rheumatology (Oxford) 2013;52:1623-9.
9. Harrold LR, Mazor KM, Peterson D et al. Patients’ knowledge and beliefs concerning gout and its treatment: a population based study. BMC Musculoskeletal Disorders 2012;13:180.
10. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann. Rheum. Dis. 2013;72:826–830.
11. Ministry of Health. Korero Marama: Health literacy and Māori. Results from the 2006 Adult Literacy and Life Skills Survey. Wellington: Ministry of Health, 2010.
12. Ministry of Health. Tupu Ola Moui Pacific Chart Book 2012. Wellington: Ministry of Health, 2012.
13. Merriman TR, Dalbeth N. The genetic basis of hyperuricaemia and gout. Joint Bone Spine. 2011;78:35–40.
14. Ministry of Health. Review of Health Education Resources on Gout Medication: Summary of report to the Ministry of Health. Wellington: Ministry of Health, 2012.
15. Dalbeth N, House ME, Horne A et al. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. BMC Musculoskeletal Disorders 2012;13:174.
16. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007;66:1311–1315.
17. Zandman-Goddard G, Amital H, Shamrayevsky N, et al. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology (Oxford) 2013;52:1126-31.
18. Riedel AA, Nelson M, Joseph-Ridge N et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31(8):1575-81.
19. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 2008;67:960–96.
20. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11:R46.
21. Cottrell E, Crabtree V, Edwards JJ, Roddy E. Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. BMC Family Practice 2013, 14:170.
22. Owens D, Whelan B, McCarthy G. A survey of the management of gout in primary care. Ir. Med. J. 2008;101:147–149.
23. Robinson PC, Merriman TR, Herbison P, Highton J. Hospital admissions associated with gout and their co-morbidities in New Zealand and England 1999–2009. Rheumatology (Oxford) 2013;52(1):118-126.
24. Reaves E, Arroll B. Management of gout in a South Auckland general practice. J Prim Health Care 2014;6(1):73–78.
25. Gow P, He J. How healthy are our patients with gout? A study of health status and management of patients with gout at two primary health care practices. Ann Rheum Dis 2014;73(Suppl2).
26. Winnard, D, Wright C, Jackson G, et al. Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice. NZ Med J 2013;126(1368):53–64.
27. Stamp LK, O’Donnell JL, Zhang M et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis & Rheumatism 2011;63(2):412–421.
28. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004;50(3):937–43.